[Special Stock] LabGenomics Soars on Expectations for Commercialization of COVID-19 Diagnostic Kit
[Asia Economy Reporter Minji Lee] LabGenomics is soaring on expectations for the commercialization of its COVID-19 diagnostic kit.
As of 3:11 PM on the 19th, LabGenomics is trading at 9,000 KRW, up 20.64% from the previous session.
LabGenomics plans to complete the development of its COVID-19 diagnostic kit and begin commercialization within this month.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Magnitude 6.3 Earthquake Strikes Northeastern Japan Sea, No Tsunami Warning
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
On the previous day, molecular diagnostics specialist Seegene launched its COVID-19 diagnostic reagent in the domestic market.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
